Testicular disorders, including male infertility and hypogonadism, are increasingly prevalent and current diagnostic tools have important limitations. The testicular microcirculation underpins ...
While guidelines state that patients with NCCN favorable intermediate risk (FIR) prostate cancer (PCa) may consider active surveillance (AS), there is a relative lack of longer term follow up data ...
Vidit Sharma describes a randomized trial testing whether salvage radiation to the prostate fossa can be safely deferred in patients with biochemical recurrence after radical prostatectomy who have ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Aim of this review is to evaluate the pharmacological efficacy and safety of Serenoa repens extracts in managing lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Using ...
At the 2026 UCSF-UCLA PSMA Conference, Jonathan Chou reviews non-PARP DNA repair targets as radiosensitizers for radiopharmaceutical therapy, highlighting a CRISPR-Cas9 functional genomics screen ...
Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHHiP radiotherapy fractionation trial in localized prostate cancer. The MMAI ...
Male ≥18 years of age at the time of signing informed consent Histologically or cytologically confirmed adenocarcinoma of the prostate For Dose Escalation: Having mCRPC that progressed after at least ...
To evaluate the safety and efficacy of Holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia when performed within 2 weeks after a transrectal prostate biopsy (PB). A ...
Silke Gillessen speaks with Neeraj Agarwal about the Advanced Prostate Cancer Consensus Conference, marking its 10th anniversary edition in Lugano. Dr. Gillessen describes APCCC's focus on daily ...
Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results